Body composition and chemotherapy toxicity among women treated for breast cancer: a systematic review.
Body composition and chemotherapy toxicity among women treated for breast cancer: a systematic review.
复制标题
接受乳腺癌治疗的女性的身体成分和化疗毒性：系统评价。
DOI：
10.1007/s11764-023-01380-7
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Robien,Kim
中科院分区：
文献类型：
--
作者：
Wopat,Heather;Harrod,Tom;Brem,RachelF;Kaltman,Rebecca;Anderson,Kendall;Robien,Kim
在接受全身化疗的乳腺癌患者中，毒性是一个重要的问题，高达60%的患者发生血液学毒性，14%的患者发生非血液学毒性。化疗是根据体表面积给药的，这不能解释瘦体重（LBM）和脂肪组织（AT）的异质性。本系统性综述在PROSPERO国际前瞻性系统性综述注册中心注册（#CRD42021279874），评估乳腺癌治疗期间身体成分与化疗相关毒性之间的关联。（PubMed，Scopus，CINAHL，和CENTRAL）于2021年11月进行了系统检索，以评估身体成分与（使用计算机断层扫描或双X射线吸收测定法评估）和接受乳腺癌治疗的女性中化疗相关毒性。资格不受出版年份或国家的限制。使用Covidence系统综述管理系统进行文章筛选和数据提取。预先确定的标准被用来评估参与者招募的严谨性，人口的代表性，并使用身体成分和toxicity. ResultsA验证措施之间的负相关性LBM和毒性的报道，在七个八个包括的研究，虽然低LBM的定义不同的研究。3项研究评价了AT与化疗毒性之间的相关性，但结果不一致。在身体成分的措施/定义和治疗方案排除的能力进行meta-analysis.ConclusionLow LBM似乎是化疗毒性的一个危险因素，但AT的作用是不清楚的。对癌症survivorsImplications进一步的研究，占化疗处方和支持性护理药物的使用指南的一致性是必要的。
PurposeToxicity is a significant problem among women receiving systemic chemotherapy for breast cancer, with up to 60% experiencing hematologic and 14% experiencing non-hematologic toxicity. Chemotherapy is dosed using body surface area, which does not account for heterogeneity in lean body mass (LBM) and adipose tissue (AT). This systematic review, registered with the PROSPERO International Prospective Register of Systematic Reviews (#CRD42021279874), evaluates associations between body composition and chemotherapy-related toxicity during breast cancer treatment.MethodsScientific literature databases (PubMed, Scopus, CINAHL, and CENTRAL) were systematically searched in November 2021 for studies evaluating associations between body composition (assessed using computed tomography or dual x-ray absorptiometry) and chemotherapy-related toxicity among women receiving breast cancer treatment. Eligibility was not limited by year or country of publication. Article screening and data abstraction was conducted using the Covidence Systematic Review Management System. Predetermined criteria were used to evaluate rigor of participant recruitment, representativeness of the population, and use of validated measures of body composition and toxicity.ResultsAn inverse association between LBM and toxicity was reported in seven of the eight included studies, although definitions of low LBM differed across studies. Three studies evaluated the association between AT and chemotherapy toxicity with inconsistent findings. Heterogeneity in body composition measures/definitions and treatment regimens precluded the ability to perform meta-analyses.ConclusionLow LBM appears to be a risk factor for chemotherapy toxicity, but the role of AT is unclear.Implications for cancer survivorsFurther research that accounts for guideline concordance in chemotherapy prescriptions and the use of supportive care medications is needed.